Details of the Drug Formulations

General Information of Drug (ID: DM7JNTV)

Drug Name
Halaven Drug Info
Synonyms
Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [1]
Bladder cancer 2C94 Phase 1/2 [2]
Cross-matching ID
PubChem CID
17755248
ChEBI ID
CHEBI:70710
CAS Number
441045-17-6
TTD ID
D0XQ5X
INTEDE ID
DR1817
ACDINA ID
D01058

Full List of Drug Formulations Containing This Drug

Eribulin Mesylate 1mg/2ml solution
Company Formulation ID FDA Description
Eisai F23158 Ethanol; Water
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2010
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)